Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Estradiol in Advanced ER+ Breast Cancer
NCT05900895Phase 1Recruiting
- Start
- Jul 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib in breast cancer. Primary endpoint: Recommended Phase II Dose at 8 weeks. Started Jul 2024; status: recruiting.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05900895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900895.